These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19456876)

  • 21. Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2010 Mar; 16(2):366-8; discussion 369-71. PubMed ID: 19811544
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.
    van Veen JJ; Maclean RM; Hampton KK; Hamer A; Makris M
    Haemophilia; 2014 Jul; 20(4):587-92. PubMed ID: 24517157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of combination FEIBA and rFVIIa bypassing therapy, with TEG profiling, in uncontrollable bleeding associated with acquired haemophilia A.
    Dunkley SM; Yang K
    Haemophilia; 2009 May; 15(3):828-30. PubMed ID: 19444979
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
    Rodríguez-Zepeda MDC; González L; Bravo A; Pompa T; Silva S; Paredes R; García J; Ramos M; Wilkinson L; Lamotte M
    Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
    Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP
    Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
    Nakamura S; Morimoto A; Oh Y; Hayase T; Kashii Y; Gunji Y; Momoi MY
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):235-7. PubMed ID: 22322137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
    Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
    Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
    Rodriguez-Merchan EC; Hedner U; Heijnen L; Jimenez-Yuste V; Lee CA; Morfini M; Querol F; Roosendaal G; Santagostino E; Solimeno LP
    Haemophilia; 2008 Nov; 14 Suppl 6():68-81. PubMed ID: 19134036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
    Stewart AJ; Hanley JP; Ludlam CA
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
    Livnat T; Martinowitz U; Zivelin A; Seligsohn U
    Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
    Siegmund B; Richter H; Pollmann H
    Haemophilia; 2005 Nov; 11(6):638-41. PubMed ID: 16236116
    [No Abstract]   [Full Text] [Related]  

  • 35. Uncomplicated neurosurgical resection of a malignant glioneuronal tumour under haemostatic cover of rFVIIa in a severe haemophilia patient with a high-titre inhibitor: a case report and literature review of rFVIIa use in major surgeries.
    Aouba A; Dezamis E; Sermet A; Rothschild C; Hermine O; Lasne D; Torchet MF
    Haemophilia; 2010 Jan; 16(1):54-60. PubMed ID: 19709314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
    Dargaud Y; Lienhart A; Meunier S; Hequet O; Chavanne H; Chamouard V; Marin S; Negrier C
    Haemophilia; 2005 Sep; 11(5):552-8. PubMed ID: 16128902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
    Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
    Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.
    Kraut EH; Aledort LM; Arkin S; Stine KC; Wong WY
    Haemophilia; 2007 Sep; 13(5):508-17. PubMed ID: 17880437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
    Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
    J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.